Myriad Genetics Investors Get Class OK in Suit Over Cancer Test

Myriad Genetics Inc. investors who say the company misled them about test efficacy and revenue may move forward with their securities suit as a class, a federal judge in Utah said.

The new class consists of everyone who acquired the Salt Lake City-based molecular diagnostic company’s common stock from Aug. 9, 2017, through and including Feb. 6, 2020, and lost money as a result, with exceptions for those with close ties to Myriad, the U.S. District Court for the District of Utah said.

The investors allege Myriad misled them about GeneSight—a pharmacogenetic test meant to predict patient responses to ...